BHVN Biohaven Ltd.

NYSE
$12.99

Biohaven Ltd. (BHVN) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.2% since its last earnings release on August 10, 2026.

Biohaven Missed Consensus Estimates
Monday, August 10, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.80)
Rev est $350M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Biohaven Ltd.

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.

Sector

Healthcare

Industry

Biotechnology

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.